# Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLC

> **NCT04912128** · — · COMPLETED · sponsor: **Peking University Third Hospital** · enrollment: 30 (actual)

## Conditions studied

- Stereotactic Body Radiation Therapy

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04912128
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-15
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-06-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04912128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04912128, "Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04912128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*